Unlike METTL3, which only increases with grade in IDH-wildtype gliomas, we demonstrated that YTHDF2 increased along with increasing WHO grades in both IDH-mutant and IDH-wildtype gliomas. Here, YTHDF2 is linked to central nervous system cancer.